JAZZ
$180.62-1.18 (-0.65%)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopat...
Recent News
Jazz Pharmaceuticals to present clinical, preclinical data at AACR 2026
Jazz Pharmaceuticals (JAZZ) announced that the company and its partners will present one oral and six poster presentations at the 2026 American Association for Cancer Research, AACR, Annual Meeting, taking place April 17-22, 2026, in San Diego. The research highlights meaningful progress across Jazz’s oncology portfolio, including new findings from company-sponsored research evaluating Ziihera, a HER2-targeted bispecific antibody; JZP898, an investigational, differentiated, conditionally activat
A Look At Jazz Pharmaceuticals (JAZZ) Valuation As New Oncology Data Heads To The 2026 AACR Meeting
Event driven spotlight on Jazz Pharmaceuticals Jazz Pharmaceuticals (JAZZ) is back on investor radars after announcing it will share new clinical and preclinical data for several oncology pipeline drugs at the 2026 American Association for Cancer Research Annual Meeting. See our latest analysis for Jazz Pharmaceuticals. The upcoming AACR oncology data arrives after a mixed price pattern, with a 30 day share price return of 8.5% and a year to date gain of 4.22%. At the same time, the 1 year...
1 Value Stock to Research Further and 2 We Ignore
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
AXSM's 2025 Revenue Surge Largely Driven by Auvelity: What's Ahead?
Axsome's lead product, Auvelity, sales jumped 74% to $507M in 2025, fueling growth while other drugs added momentum.
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 3.8% return has closely followed the S&P 500.